Total Payments
$12,667
2024 Payments
$745.62
Companies
43
Transactions
128
Medicare Patients
1,899
Medicare Billing
$765,991
Payment Breakdown by Category
Research$8,848 (69.8%)
Food & Beverage$3,752 (29.6%)
Education$67.06 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,848 | 1 | 69.8% |
| Food and Beverage | $3,752 | 124 | 29.6% |
| Education | $67.06 | 3 | 0.5% |
Payments by Type
Research
$8,848
1 transactions
General
$3,819
127 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Servier BioInnovation | $8,848 | 1 | $0 (2022) |
| Amgen Inc. | $451.42 | 9 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $428.13 | 4 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $386.19 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $221.11 | 12 | $0 (2024) |
| Celgene Corporation | $187.85 | 5 | $0 (2022) |
| Genentech USA, Inc. | $170.75 | 9 | $0 (2022) |
| GlaxoSmithKline, LLC. | $168.45 | 4 | $0 (2024) |
| Merck Sharp & Dohme LLC | $143.14 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $137.48 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $745.62 | 27 | GlaxoSmithKline, LLC. ($168.45) |
| 2023 | $58.16 | 3 | Seagen Inc. ($22.24) |
| 2022 | $10,174 | 63 | Servier BioInnovation ($8,848) |
| 2021 | $79.61 | 5 | AstraZeneca Pharmaceuticals LP ($20.38) |
| 2019 | $122.68 | 1 | Janssen Pharmaceuticals, Inc ($122.68) |
| 2018 | $894.04 | 13 | Amgen Inc. ($250.77) |
| 2017 | $592.56 | 16 | E.R. Squibb & Sons, L.L.C. ($138.61) |
All Payment Transactions
128 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $31.51 | General |
| Category: Oncology | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Oncology | ||||||
| 09/11/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $28.23 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.46 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.25 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 07/18/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: Oncology | ||||||
| 07/18/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: HEMATOLOGY | ||||||
| 07/15/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: NONE | ||||||
| 07/12/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.14 | General |
| Category: Hematology/Oncology | ||||||
| 07/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.30 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: Oncology | ||||||
| 06/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $39.60 | General |
| Category: Oncology | ||||||
| 06/07/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Oncology | ||||||
| 06/06/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $28.73 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $30.20 | General |
| Category: Oncology | ||||||
| 05/16/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CALASPARGASE PEGOL IN ADULTS WITH ALL | Servier BioInnovation | $8,848 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 217 | 551 | $79,400 | $16,935 |
| 2022 | 30 | 1,164 | 58,954 | $2.1M | $588,523 |
| 2021 | 17 | 518 | 9,280 | $538,338 | $160,532 |
Total Patients
1,899
Total Services
68,785
Medicare Billing
$765,991
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 45 | 64 | $24,347 | $6,455 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $14,827 | $4,037 | 27.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 18 | 23 | $11,367 | $2,395 | 21.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 19 | 23 | $5,526 | $1,228 | 22.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 23 | $5,701 | $1,115 | 19.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 26 | 40 | $5,295 | $948.00 | 17.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 34 | $3,163 | $391.06 | 12.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 17 | $1,306 | $218.77 | 16.7% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 11 | 130 | $7,727 | $109.37 | 1.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 20 | 24 | $80.40 | $21.23 | 26.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 151 | $60.40 | $14.66 | 24.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 66 | 18,000 | $804,600 | $305,753 | 38.0% |
| Q5122 | Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg | Office | 2022 | 12 | 396 | $320,966 | $73,659 | 22.9% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2022 | 30 | 6,950 | $215,937 | $44,447 | 20.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 71 | 333 | $164,569 | $37,680 | 22.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 75 | 261 | $64,699 | $15,716 | 24.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2022 | 14 | 20,400 | $41,820 | $14,812 | 35.4% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2022 | 12 | 102 | $55,212 | $14,575 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 112 | 151 | $52,722 | $13,401 | 25.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 70 | 70 | $47,927 | $12,152 | 25.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 68 | 409 | $45,904 | $10,300 | 22.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 40 | 139 | $33,393 | $7,688 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 51 | 51 | $23,925 | $6,985 | 29.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 81 | 483 | $39,039 | $5,594 | 14.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 25 | 91 | $22,274 | $5,011 | 22.5% |
About Dr. Lawrence Tepper, D.O
Dr. Lawrence Tepper, D.O is a Hematology healthcare provider based in Key West, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528033958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Tepper, D.O has received a total of $12,667 in payments from pharmaceutical and medical device companies, with $745.62 received in 2024. These payments were reported across 128 transactions from 43 companies. The most common payment nature is "" ($8,848).
As a Medicare-enrolled provider, Tepper has provided services to 1,899 Medicare beneficiaries, totaling 68,785 services with total Medicare billing of $765,991. Data is available for 3 years (2021–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology
- Location Key West, FL
- Active Since 02/21/2006
- Last Updated 07/06/2021
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1528033958
Products in Payments
- XARELTO (Drug) $428.13
- REBLOZYL (Biological) $172.58
- OJJAARA (Drug) $168.45
- Revlimid (Drug) $149.34
- KEYTRUDA (Biological) $143.14
- OPDIVO (Biological) $142.64
- Prolia (Biological) $142.43
- LIBTAYO (Biological) $142.02
- Nplate (Biological) $141.80
- XGEVA (Biological) $123.00
- KYPHON Balloon Kyphoplasty (Device) $118.17
- GENERAL STENTS (Device) $116.69
- ELIQUIS (Drug) $109.48
- Enhertu (Drug) $105.16
- AVYCAZ (Drug) $100.00
- LYNPARZA (Drug) $75.84
- Rubraca (Drug) $75.60
- ZEPZELCA (Drug) $69.90
- XPOVIO (Drug) $66.18
- KISQALI (Drug) $60.70
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.